The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical Application of the 70-Gene Profile: The MINDACT Trial
Abstract
The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“Recognizing the need for better prognostic tools, investigators at the Netherlands Cancer Institute used microarray technology to develop a 70-gene gene expression profile that, used as a dichotomous risk classifier, seemed to accurately discriminate between patients at low and high risk of distant relapse.(7) This cl…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Self-citationSotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Cited by
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Self-citationFeng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992
“To remove cells with low-quality sequencing values, four filtering criteria were applied: (1) number of total reads; (2) mapping rate; (3) number of detected genes; and (4) portion of intergenic region.”
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
“Studies evaluating the prognostic performance of gene signatures in breast cancer have driven important clinical trials, such as MINDACT (NCT00433589”
MethodI-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2560-8 · Cited by 601
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., Snider, J., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0129-6 · Cited by 542
Hugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
Weigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
Schnitt, S. J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.33 · Cited by 419
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Ulloa-Montoya, F., Louahed, J., Dizier, B., Gruselle, O., Spiessens, B., Lehmann, F. F., Suciu, S., Kruit, W. H. J., Eggermont, A. M. M., Vansteenkiste, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3762 · Cited by 436
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Azim, H. A., Michiels, S., Bedard, P. L., Singhal, S. K., Criscitiello, C., Ignatiadis, M., Haibe-Kains, B., Piccart, M. J., Sotiriou, C., & Loi, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2599 · Cited by 399
Self-citationThe I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1895-2 · Cited by 362
Self-citationGene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
Subramanian, J., & Simon, R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq025 · Cited by 351
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells
Bartucci, M., Dattilo, R., Moriconi, C., Pagliuca, A., Mottolese, M., Federici, G., Benedetto, A. D., Todaro, M., Stassi, G., Sperati, F., et al. (2015) · Oncogene · doi:10.1038/onc.2014.5 · Cited by 350
Strategies for the discovery and development of therapies for metastatic breast cancer
Eckhardt, B. L., Francis, P. A., Parker, B. S., & Anderson, R. L. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2372 · Cited by 349
Kao, K.-J., Chang, K.-M., Hsu, H.-C., & Huang, A. T. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-143 · Cited by 348
A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Nault, J., De Reyniès, A., Villanueva, A., Calderaro, J., Rebouissou, S., Couchy, G., Decaens, T., Franco, D., Imbeaud, S., Rousseau, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.051 · Cited by 338
Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Nielsen, T., Wallden, B., Schaper, C., Ferree, S., Liu, S., Gao, D., Barry, G., Dowidar, N., Maysuria, M., & Storhoff, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-177 · Cited by 311
A new genome‐driven integrated classification of breast cancer and its implications
Dawson, S., Rueda, O. M., Aparicio, S., & Caldas, C. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.19 · Cited by 306
Practical implications of gene-expression-based assays for breast oncologists
Prat, A., Ellis, M. J., & Perou, C. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.178 · Cited by 295
Molecular Diagnosis of Antibody-Mediated Rejection in Human Kidney Transplants
Sellarés, J., Reeve, J., Loupy, A., Mengel, M., Sis, B., Skene, A., de Freitas, D. G., Kreepala, C., Hidalgo, L. G., Famulski, K. S., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12150 · Cited by 280
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A., Hauptmann, M., van de Vijver, M. J., Koornstra, R. H. T., Bueno-de-Mesquita, J. M., Linn, S. C., & van ’t Veer, L. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0814-2 · Cited by 267
Self-citationDowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 267
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Straver, M. E., Glas, A. M., Hannemann, J., Wesseling, J., van de Vijver, M. J., Rutgers, E. J. T., Vrancken Peeters, M.-J. T. F. D., van Tinteren, H., van‘t Veer, L. J., & Rodenhuis, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0333-1 · Cited by 252
Self-citationBoudreau, A., van't Veer, L. J., & Bissell, M. J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20880 · Cited by 43
Self-citationMills, M., Liveringhouse, C., Lee, F., Nanda, R. H., Ahmed, K. A., Washington, I. R., Thapa, R., Fridley, B. L., Blumencranz, P., Extermann, M., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.08.007 · Cited by 7
“com) to determine clinical risk, as used by the MINDACT trial [5].”
BackgroundMethod
Metadata
- Authors
- Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S., & Piccart-Gebhart, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-10
- Volume
- 26
- Issue
- 5
- Pages
- 729-735
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2143858250
- Cited by
- 464
- References
- 23
- FWCI
- 19.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.